Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 49

1.

Discovery of a First-in-Class Receptor Interacting Protein 2 (RIP2) Kinase Specific Clinical Candidate, 2-((4-(Benzo[d]thiazol-5-ylamino)-6-(tert-butylsulfonyl)quinazolin-7-yl)oxy)ethyl Dihydrogen Phosphate, for the Treatment of Inflammatory Diseases.

Haile PA, Casillas LN, Votta BJ, Wang GZ, Charnley AK, Dong X, Bury MJ, Romano JJ, Mehlmann JF, King BW, Erhard KF, Hanning CR, Lipshutz DB, Desai BM, Capriotti CA, Schaeffer MC, Berger SB, Mahajan MK, Reilly MA, Nagilla R, Rivera EJ, Sun HH, Kenna JK, Beal AM, Ouellette MT, Kelly M, Stemp G, Convery MA, Vossenkämper A, MacDonald TT, Gough PJ, Bertin J, Marquis RW.

J Med Chem. 2019 Jul 25;62(14):6482-6494. doi: 10.1021/acs.jmedchem.9b00575. Epub 2019 Jul 2.

PMID:
31265286
2.

Preclinical evaluation of EPHX2 inhibition as a novel treatment for inflammatory bowel disease.

Reisdorf WC, Xie Q, Zeng X, Xie W, Rajpal N, Hoang B, Burgert ME, Kumar V, Hurle MR, Rajpal DK, O'Donnell S, MacDonald TT, Vossenkämper A, Wang L, Reilly M, Votta BJ, Sanchez Y, Agarwal P.

PLoS One. 2019 Apr 19;14(4):e0215033. doi: 10.1371/journal.pone.0215033. eCollection 2019.

3.

Identification of Quinoline-Based RIP2 Kinase Inhibitors with an Improved Therapeutic Index to the hERG Ion Channel.

Haile PA, Casillas LN, Bury MJ, Mehlmann JF, Singhaus R Jr, Charnley AK, Hughes TV, DeMartino MP, Wang GZ, Romano JJ, Dong X, Plotnikov NV, Lakdawala AS, Convery MA, Votta BJ, Lipshutz DB, Desai BM, Swift B, Capriotti CA, Berger SB, Mahajan MK, Reilly MA, Rivera EJ, Sun HH, Nagilla R, LePage C, Ouellette MT, Totoritis RD, Donovan BT, Brown BS, Chaudhary KW, Gough PJ, Bertin J, Marquis RW.

ACS Med Chem Lett. 2018 Sep 26;9(10):1039-1044. doi: 10.1021/acsmedchemlett.8b00344. eCollection 2018 Oct 11.

4.

The Resting Potential and K+ Currents in Primary Human Articular Chondrocytes.

Maleckar MM, Clark RB, Votta B, Giles WR.

Front Physiol. 2018 Sep 4;9:974. doi: 10.3389/fphys.2018.00974. eCollection 2018.

5.

S100A12 and S100A8/9 proteins are biomarkers of articular disease activity in Blau syndrome.

Wang L, Rosé CD, Foley KP, Anton J, Bader-Meunier B, Brissaud P, Chédeville G, Cimaz R, Fernández-Martín J, Guly C, Hachulla E, Harjacek M, Mackensen F, Merino R, Modesto C, Naranjo Hernández A, Pajot C, Ramanan AV, Thatayatikom A, Thomée C, Vastert S, Votta BJ, Bertin J, Wouters CH.

Rheumatology (Oxford). 2018 Apr 7. doi: 10.1093/rheumatology/key090. [Epub ahead of print]

PMID:
29635517
6.

Randomized clinical study of safety, pharmacokinetics, and pharmacodynamics of RIPK1 inhibitor GSK2982772 in healthy volunteers.

Weisel K, Scott NE, Tompson DJ, Votta BJ, Madhavan S, Povey K, Wolstenholme A, Simeoni M, Rudo T, Richards-Peterson L, Sahota T, Wang JG, Lich J, Finger J, Verticelli A, Reilly M, Gough PJ, Harris PA, Bertin J, Wang ML.

Pharmacol Res Perspect. 2017 Dec;5(6). doi: 10.1002/prp2.365.

7.

Identification of an antibody-based immunoassay for measuring direct target binding of RIPK1 inhibitors in cells and tissues.

Finger JN, Brusq JM, Campobasso N, Cook MN, Deutsch J, Haag H, Harris PA, Jenkins EL, Joglekar D, Lich JD, Maguire S, Nagilla R, Rivera EJ, Sun H, Votta BJ, Bertin J, Gough PJ.

Pharmacol Res Perspect. 2017 Dec;5(6). doi: 10.1002/prp2.377.

8.

The Identification and Pharmacological Characterization of 6-(tert-Butylsulfonyl)-N-(5-fluoro-1H-indazol-3-yl)quinolin-4-amine (GSK583), a Highly Potent and Selective Inhibitor of RIP2 Kinase.

Haile PA, Votta BJ, Marquis RW, Bury MJ, Mehlmann JF, Singhaus R Jr, Charnley AK, Lakdawala AS, Convery MA, Lipshutz DB, Desai BM, Swift B, Capriotti CA, Berger SB, Mahajan MK, Reilly MA, Rivera EJ, Sun HH, Nagilla R, Beal AM, Finger JN, Cook MN, King BW, Ouellette MT, Totoritis RD, Pierdomenico M, Negroni A, Stronati L, Cucchiara S, Ziółkowski B, Vossenkämper A, MacDonald TT, Gough PJ, Bertin J, Casillas LN.

J Med Chem. 2016 May 26;59(10):4867-80. doi: 10.1021/acs.jmedchem.6b00211. Epub 2016 May 4.

PMID:
27109867
9.

Crystal structures of human RIP2 kinase catalytic domain complexed with ATP-competitive inhibitors: Foundations for understanding inhibitor selectivity.

Charnley AK, Convery MA, Lakdawala Shah A, Jones E, Hardwicke P, Bridges A, Ouellette M, Totoritis R, Schwartz B, King BW, Wisnoski DD, Kang J, Eidam PM, Votta BJ, Gough PJ, Marquis RW, Bertin J, Casillas L.

Bioorg Med Chem. 2015 Nov 1;23(21):7000-6. doi: 10.1016/j.bmc.2015.09.038. Epub 2015 Sep 25.

PMID:
26455654
10.

Catalytic in vivo protein knockdown by small-molecule PROTACs.

Bondeson DP, Mares A, Smith IE, Ko E, Campos S, Miah AH, Mulholland KE, Routly N, Buckley DL, Gustafson JL, Zinn N, Grandi P, Shimamura S, Bergamini G, Faelth-Savitski M, Bantscheff M, Cox C, Gordon DA, Willard RR, Flanagan JJ, Casillas LN, Votta BJ, den Besten W, Famm K, Kruidenier L, Carter PS, Harling JD, Churcher I, Crews CM.

Nat Chem Biol. 2015 Aug;11(8):611-7. doi: 10.1038/nchembio.1858. Epub 2015 Jun 10.

11.

RIP3 induces apoptosis independent of pronecrotic kinase activity.

Mandal P, Berger SB, Pillay S, Moriwaki K, Huang C, Guo H, Lich JD, Finger J, Kasparcova V, Votta B, Ouellette M, King BW, Wisnoski D, Lakdawala AS, DeMartino MP, Casillas LN, Haile PA, Sehon CA, Marquis RW, Upton J, Daley-Bauer LP, Roback L, Ramia N, Dovey CM, Carette JE, Chan FK, Bertin J, Gough PJ, Mocarski ES, Kaiser WJ.

Mol Cell. 2014 Nov 20;56(4):481-95. doi: 10.1016/j.molcel.2014.10.021. Epub 2014 Nov 20.

12.

The immune receptor NOD1 and kinase RIP2 interact with bacterial peptidoglycan on early endosomes to promote autophagy and inflammatory signaling.

Irving AT, Mimuro H, Kufer TA, Lo C, Wheeler R, Turner LJ, Thomas BJ, Malosse C, Gantier MP, Casillas LN, Votta BJ, Bertin J, Boneca IG, Sasakawa C, Philpott DJ, Ferrero RL, Kaparakis-Liaskos M.

Cell Host Microbe. 2014 May 14;15(5):623-35. doi: 10.1016/j.chom.2014.04.001. Epub 2014 Apr 17.

13.

A key role for the endothelium in NOD1 mediated vascular inflammation: comparison to TLR4 responses.

Gatheral T, Reed DM, Moreno L, Gough PJ, Votta BJ, Sehon CA, Rickard DJ, Bertin J, Lim E, Nicholson AG, Mitchell JA.

PLoS One. 2012;7(8):e42386. doi: 10.1371/journal.pone.0042386. Epub 2012 Aug 1.

14.
15.

Voltage-gated K+ currents in mouse articular chondrocytes regulate membrane potential.

Clark RB, Hatano N, Kondo C, Belke DD, Brown BS, Kumar S, Votta BJ, Giles WR.

Channels (Austin). 2010 May-Jun;4(3):179-91.

PMID:
20372061
16.

Neuropathology of olfactory ensheathing cell transplantation into the brain of two amyotrophic lateral sclerosis (ALS) patients.

Giordana MT, Grifoni S, Votta B, Magistrello M, Vercellino M, Pellerino A, Navone R, Valentini C, Calvo A, Chiò A.

Brain Pathol. 2010 Jul;20(4):730-7. doi: 10.1111/j.1750-3639.2009.00353.x. Epub 2009 Oct 27.

PMID:
19919605
17.

Functional characterization of TRPV4 as an osmotically sensitive ion channel in porcine articular chondrocytes.

Phan MN, Leddy HA, Votta BJ, Kumar S, Levy DS, Lipshutz DB, Lee SH, Liedtke W, Guilak F.

Arthritis Rheum. 2009 Oct;60(10):3028-37. doi: 10.1002/art.24799.

18.

N-CAM dysfunction and unexpected accumulation of PSA-NCAM in brain of adult-onset autosomal-dominant leukodystrophy.

Piccinini M, Buccinnà B, De Marco G, Lupino E, Ramondetti C, Grifoni S, Votta B, Giordana MT, Rinaudo MT.

Brain Pathol. 2010 Mar;20(2):431-40. doi: 10.1111/j.1750-3639.2009.00313.x. Epub 2009 Jun 25.

PMID:
19725832
19.

Alterations of myelin-specific proteins and sphingolipids characterize the brains of acid sphingomyelinase-deficient mice, an animal model of Niemann-Pick disease type A.

Buccinnà B, Piccinini M, Prinetti A, Scandroglio F, Prioni S, Valsecchi M, Votta B, Grifoni S, Lupino E, Ramondetti C, Schuchman EH, Giordana MT, Sonnino S, Rinaudo MT.

J Neurochem. 2009 Apr;109(1):105-15. doi: 10.1111/j.1471-4159.2009.05947.x. Epub 2009 Feb 2.

20.

Involvement of the choroid plexus in multiple sclerosis autoimmune inflammation: a neuropathological study.

Vercellino M, Votta B, Condello C, Piacentino C, Romagnolo A, Merola A, Capello E, Mancardi GL, Mutani R, Giordana MT, Cavalla P.

J Neuroimmunol. 2008 Aug 13;199(1-2):133-41. doi: 10.1016/j.jneuroim.2008.04.035. Epub 2008 Jun 9.

PMID:
18539342
21.

Systemic activation of the transient receptor potential vanilloid subtype 4 channel causes endothelial failure and circulatory collapse: Part 2.

Willette RN, Bao W, Nerurkar S, Yue TL, Doe CP, Stankus G, Turner GH, Ju H, Thomas H, Fishman CE, Sulpizio A, Behm DJ, Hoffman S, Lin Z, Lozinskaya I, Casillas LN, Lin M, Trout RE, Votta BJ, Thorneloe K, Lashinger ES, Figueroa DJ, Marquis R, Xu X.

J Pharmacol Exp Ther. 2008 Aug;326(2):443-52. doi: 10.1124/jpet.107.134551. Epub 2008 May 22. Erratum in: J Pharmacol Exp Ther. 2011 Jul;338(1):408-9.

PMID:
18499744
22.

N-((1S)-1-{[4-((2S)-2-{[(2,4-dichlorophenyl)sulfonyl]amino}-3-hydroxypropanoyl)-1-piperazinyl]carbonyl}-3-methylbutyl)-1-benzothiophene-2-carboxamide (GSK1016790A), a novel and potent transient receptor potential vanilloid 4 channel agonist induces urinary bladder contraction and hyperactivity: Part I.

Thorneloe KS, Sulpizio AC, Lin Z, Figueroa DJ, Clouse AK, McCafferty GP, Chendrimada TP, Lashinger ES, Gordon E, Evans L, Misajet BA, Demarini DJ, Nation JH, Casillas LN, Marquis RW, Votta BJ, Sheardown SA, Xu X, Brooks DP, Laping NJ, Westfall TD.

J Pharmacol Exp Ther. 2008 Aug;326(2):432-42. doi: 10.1124/jpet.108.139295. Epub 2008 May 22. Erratum in: J Pharmacol Exp Ther. 2011 Jul;338(1):410.

PMID:
18499743
23.

Interleukin-1 inhibits osmotically induced calcium signaling and volume regulation in articular chondrocytes.

Pritchard S, Votta BJ, Kumar S, Guilak F.

Osteoarthritis Cartilage. 2008 Dec;16(12):1466-73. doi: 10.1016/j.joca.2008.04.003. Epub 2008 May 20.

24.

Altered glutamate reuptake in relapsing-remitting and secondary progressive multiple sclerosis cortex: correlation with microglia infiltration, demyelination, and neuronal and synaptic damage.

Vercellino M, Merola A, Piacentino C, Votta B, Capello E, Mancardi GL, Mutani R, Giordana MT, Cavalla P.

J Neuropathol Exp Neurol. 2007 Aug;66(8):732-9.

PMID:
17882017
25.

Intermittent treatment with parathyroid hormone (PTH) as well as a non-peptide small molecule agonist of the PTH1 receptor inhibits adipocyte differentiation in human bone marrow stromal cells.

Rickard DJ, Wang FL, Rodriguez-Rojas AM, Wu Z, Trice WJ, Hoffman SJ, Votta B, Stroup GB, Kumar S, Nuttall ME.

Bone. 2006 Dec;39(6):1361-72. Epub 2006 Aug 10.

PMID:
16904389
26.

Grey matter pathology in multiple sclerosis.

Vercellino M, Plano F, Votta B, Mutani R, Giordana MT, Cavalla P.

J Neuropathol Exp Neurol. 2005 Dec;64(12):1101-7.

PMID:
16319720
27.

Inhibition of colony-stimulating-factor-1 signaling in vivo with the orally bioavailable cFMS kinase inhibitor GW2580.

Conway JG, McDonald B, Parham J, Keith B, Rusnak DW, Shaw E, Jansen M, Lin P, Payne A, Crosby RM, Johnson JH, Frick L, Lin MH, Depee S, Tadepalli S, Votta B, James I, Fuller K, Chambers TJ, Kull FC, Chamberlain SD, Hutchins JT.

Proc Natl Acad Sci U S A. 2005 Nov 1;102(44):16078-83. Epub 2005 Oct 25.

28.

A new dimeric dihydrochalcone and a new prenylated flavone from the bud covers of Artocarpus altilis: potent inhibitors of cathepsin K.

Patil AD, Freyer AJ, Killmer L, Offen P, Taylor PB, Votta BJ, Johnson RK.

J Nat Prod. 2002 Apr;65(4):624-7.

PMID:
11975520
29.

IL-1- and TNF-induced bone resorption is mediated by p38 mitogen activated protein kinase.

Kumar S, Votta BJ, Rieman DJ, Badger AM, Gowen M, Lee JC.

J Cell Physiol. 2001 Jun;187(3):294-303.

PMID:
11319753
30.

Inhibition of p38 MAP kinase as a therapeutic strategy.

Lee JC, Kumar S, Griswold DE, Underwood DC, Votta BJ, Adams JL.

Immunopharmacology. 2000 May;47(2-3):185-201. Review.

PMID:
10878289
31.

Antagonizing the parathyroid calcium receptor stimulates parathyroid hormone secretion and bone formation in osteopenic rats.

Gowen M, Stroup GB, Dodds RA, James IE, Votta BJ, Smith BR, Bhatnagar PK, Lago AM, Callahan JF, DelMar EG, Miller MA, Nemeth EF, Fox J.

J Clin Invest. 2000 Jun;105(11):1595-604.

32.

CKbeta-8 [CCL23], a novel CC chemokine, is chemotactic for human osteoclast precursors and is expressed in bone tissues.

Votta BJ, White JR, Dodds RA, James IE, Connor JR, Lee-Rykaczewski E, Eichman CF, Kumar S, Lark MW, Gowen M.

J Cell Physiol. 2000 May;183(2):196-207.

PMID:
10737895
33.

Identification and cloning of a connective tissue growth factor-like cDNA from human osteoblasts encoding a novel regulator of osteoblast functions.

Kumar S, Hand AT, Connor JR, Dodds RA, Ryan PJ, Trill JJ, Fisher SM, Nuttall ME, Lipshutz DB, Zou C, Hwang SM, Votta BJ, James IE, Rieman DJ, Gowen M, Lee JC.

J Biol Chem. 1999 Jun 11;274(24):17123-31.

34.

Peptide aldehyde inhibitors of cathepsin K inhibit bone resorption both in vitro and in vivo.

Votta BJ, Levy MA, Badger A, Bradbeer J, Dodds RA, James IE, Thompson S, Bossard MJ, Carr T, Connor JR, Tomaszek TA, Szewczuk L, Drake FH, Veber DF, Gowen M.

J Bone Miner Res. 1997 Sep;12(9):1396-406.

35.
36.

Cytokine suppressive anti-inflammatory compounds inhibit bone resorption in vitro.

Votta BJ, Bertolini DR.

Bone. 1994 Sep-Oct;15(5):533-8.

PMID:
7980964
37.
38.

Bicyclic imidazoles as a novel class of cytokine biosynthesis inhibitors.

Lee JC, Badger AM, Griswold DE, Dunnington D, Truneh A, Votta B, White JR, Young PR, Bender PE.

Ann N Y Acad Sci. 1993 Nov 30;696:149-70. Review. No abstract available.

PMID:
8109825
39.
40.

Characterization of the soluble leukotriene B4 receptor from sheep lung membranes.

Votta B, Keefer J, Mong S.

Biochem J. 1990 Aug 15;270(1):213-8.

41.
42.

15-Acetylthioxy-furodysinin lactone, isolated from a marine sponge Dysidea, sp. is a potent agonist to human leukotriene B4 receptor.

Mong S, Votta B, Sarau HM, Foley JJ, Schmidt D, Carte BK, Poehland B, Westley J.

Prostaglandins. 1990 Jan;39(1):89-97.

PMID:
2155439
44.

Inhibitory effect of SK&F 86002 on monocyte IL-1 production.

Lee JC, Votta B, Griswold DE, Hanna N.

Agents Actions. 1989 Jun;27(3-4):280-1.

PMID:
2801311
45.

Inhibition of monocyte IL-1 production by the anti-inflammatory compound, SK&F 86002.

Lee JC, Griswold DE, Votta B, Hanna N.

Int J Immunopharmacol. 1988;10(7):835-43.

PMID:
3148560
46.

Effect of auranofin treatment on aberrant splenic interleukin production in adjuvant arthritic rats.

Lee JC, Dimartino MJ, Votta BJ, Hanna N.

J Immunol. 1987 Nov 15;139(10):3268-74.

PMID:
3500212
47.
48.

Macrophage activation in rat models of inflammation and arthritis. Systemic activation precedes arthritis induction and progression.

Johnson WJ, Muirhead KA, Meunier PC, Votta BJ, Schmitt TC, DiMartino MJ, Hanna N.

Arthritis Rheum. 1986 Sep;29(9):1122-30.

PMID:
3489469
49.

Immunocytochemical evidence for 3',5'-cGMP and 3',5'-cGMP-dependent protein kinase involvement in lymphocyte proliferation.

Largen MT, Votta B.

J Cyclic Nucleotide Protein Phosphor Res. 1983;9(3):231-44.

PMID:
6321574

Supplemental Content

Support Center